美国国防部将药明康德移出「中国军事企业」名单：执行法院禁令，保留以补充理由重新列名的可能
华盛顿 — 美国国防部11月9日在《联邦纪事》刊登通知，将中国生物医药外包企业药明康德移出依第1260H条维护的「中国军事企业」名单。通知由国防部负责采办与保障的副部长办公室发出，称移出决定是为了执行哥伦比亚特区联邦地区法院8月7日的命令，该命令批准了药明康德的初步禁令请求，禁止国防部执行或落实这项认定。
国防部今年6月8日把这份名单扩充至188家实体，药明康德被新增列名、被认定为「中国军事企业」。药明康德6月11日向哥伦比亚特区联邦地区法院提起诉讼，称这项认定不合法，已给公司造成重大的声誉、商业与运营损害；法院8月批准初步禁令后，认定在诉讼期间不得执行。
国防部在通知中同时表示，这次移出「不妨碍以补充或新的理由重新列名」。药明康德已在香港交易所披露这一进展。
后续风险并未完全消除。药明康德总法律顾问 Howard Wu 此前在业绩电话会上表示，公司仍可能被管理和预算办公室依《生物安全法案》列为「受关注生物技术公司」，该名单预计在2026年年底前公布；他同时表示，目前尚未获悉任何拟议的列名或通知。
药明康德总部位于中国，是一家为全球药企提供研发与生产外包服务的企业，在美国设有运营与生产设施。这起诉讼的实体审理仍在进行中。（来源：美国国防部）
Pentagon Removes WuXi AppTec From 'Chinese Military Companies' List, Complying With Court Injunction While Reserving the Right to Relist
WASHINGTON — The U.S. Department of Defense announced in a Federal Register notice on November 9 that it has removed Chinese biopharmaceutical outsourcing company WuXi AppTec from the list of 'Chinese military companies' maintained under Section 1260H. The notice, issued by the Office of the Under Secretary of Defense for Acquisition and Sustainment, said the removal complies with an August 7 order by the U.S. District Court for the District of Columbia, which granted WuXi AppTec's motion for a preliminary injunction barring the department from enforcing or giving effect to the designation.
The Pentagon had expanded the list to 188 entities on June 8, newly designating WuXi AppTec as a 'Chinese military company.' WuXi AppTec sued in federal court in Washington on June 11, arguing the designation was unlawful and had inflicted substantial reputational, commercial and operational harm; the court granted the preliminary injunction in August, suspending enforcement while the case proceeds.
The department added that the delisting is 'without prejudice to relisting the company on additional or supplementary grounds.' WuXi AppTec has disclosed the development in a filing with the Hong Kong Stock Exchange.
The risk has not fully receded. General Counsel Howard Wu said on an earnings call last month that the company could still be named a 'biotechnology company of concern' under the BIOSECURE Act by the Office of Management and Budget, whose list is expected by the end of 2026; he said the company is not aware of any proposed designation or notice so far.
Headquartered in China, WuXi AppTec provides research, development and manufacturing services to drugmakers worldwide and operates facilities in the United States. The merits phase of its lawsuit is still pending. (Source: U.S. Department of Defense)
来源：美国国防部
发布：GSM·美国（发布链接）
图片来源：图：五角大楼航拍（资料图），本站档案图复用。 / Photo: Aerial view of the Pentagon (file photo), GSM archive image reused.
GSM Global · 本篇英文版 English edition of this story
